Molecular pathogenesis of Epstein-Barr virus associated posttransplant lymphomas: new insights through latent membrane protein 1 fingerprinting.
BACKGROUND
Fingerprint amino acid patterns within the carboxy terminus of the latent membrane protein (LMP1) oncoprotein of Epstein-Barr virus (EBV) allow individual strain identification at the molecular level. LMP1 is expressed in the tumor cells of EBV-associated posttransplant lymphomas (PTLs) and the LMP1 genome is also identified in lymphocytes of most donors of allogeneic bone marrow. Therefore, LMP1 genotyping in donor lymphocytes and PTL tumor cells, together with sex chromatin determination of tumor cells, allows to determine the origin of PTL tumor cells and the origin of individual EBV strains harboured by them.


METHODS
We traced the origin of aggressive PTLs occurring in six patients after allogeneic T cell-depleted stem cell transplantation (allo-SCT). DNA was extracted from donor lymphocytes and PTLs of recipients and amplified with LMP1-specific primers in each case. A comparative sequence analysis of the fingerprint LMP1 region identified in donor lymphocytes and lymphoma was performed.


RESULTS
One lymphoma of donor origin occurred after highly selected CD34+ PBSCT and contained the same LMP1 genotype as the donor lymphocytes. Three lymphomas of recipient origin had deletions within the carboxy terminus of LMP1, not identified in the donor strains. All lymphomas occurred in the setting of allo-SCT and had a rapid clinical course.


CONCLUSIONS
These results show that highly selected CD34+ PBSCT does not protect against transfer of EBV positive founder cells of donor type PTL and that, after allo-SCT, recipient type PTLs are not uncommon. Outgrowth of recipient type lymphoma may be favoured by LMP1 deletion variant strains present in recipient lymphocytes.
Schäfer
H
H
Department of Internal Medicine, Eberhard-Karls-University, Tübingen, Germany.
Berger
C
C
Aepinus
C
C
Hebart
H
H
Beck
R
R
Kaiserling
E
E
Kanz
L
L
Einsele
H
H
Knecht
H
H
D000328:Adult; D018952:Antigens, CD34 / Q000032:analysis; D003586:Cytomegalovirus Infections / Q000150:complications*; D016172:DNA Fingerprinting; D005260:Female; D017353:Gene Deletion; D005838:Genotype; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006412:Hematopoietic Stem Cells / Q000276:immunology; D006801:Humans; D016393:Lymphoma, B-Cell / Q000209:etiology* / Q000821:virology*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000209:etiology* / Q000821:virology*; D008297:Male; D008875:Middle Aged; D014019:Tissue Donors; D014184:Transplantation, Homologous / Q000009:adverse effects; D014763:Viral Matrix Proteins / Q000235:genetics
D018952:Antigens, CD34; C037662:EBV-associated membrane antigen, Epstein-Barr virus; D014763:Viral Matrix Proteins